Document is current
Any future updates will be listed below
-
Authors
Mandel, Ilana https://orcid.org/0000-0002-4488-5408
Haves Ziv, Dana
Goldshtein, Ilana
Peretz, Tsuri
Alishekevitz, Dror
Fridman Dror, Anna
Hakim, Motti
Hashmueli, Sharon
Friedman, Itay
Sapir, Yair
Greco, Rita
Qu, Hongjing
Nestle, Frank
Wiederschain, Dmitri
Pao, Lily
Sharma, Sharad https://orcid.org/0000-0001-7743-3910
Ben Moshe, Tehila
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04717375 at ClinicalTrials.govDocuments that mention this clinical trial
623 Final results from phase 1, first-in-human, dose escalation study of a first-in-class anti-ILT2 antibody, SAR444881, alone and with pembrolizumab or cetuximab, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0623
BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression
https://doi.org/10.1136/jitc-2022-004859
-
Funding
Funding for this research was provided by:
Biond Biologics
Sanofi
- License Information
